Copertina

Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jingmin Zhou, Mansoor Husain, Yang Li, Wenyan Liu, Zewei Shen, Tina Vilsbøll, Junbo Ge
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
di: Linong Ji, et al.
Pubblicazione: (2024)

Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
di: Jingyu Wang, et al.
Pubblicazione: (2024)

Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5
di: Tina Vilsbøll, et al.
Pubblicazione: (2025)

Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER ‐2 trial emulation with real‐world data
di: Gian Paolo Fadini, et al.
Pubblicazione: (2025)

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials
di: Francesco Zaccardi, et al.
Pubblicazione: (2026)

Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial
di: Francesco Cosentino, et al.
Pubblicazione: (2024)

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia
di: Hussein ElBadawi, et al.
Pubblicazione: (2025)

Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial
di: Melissa‐Rosina Pasqua, et al.
Pubblicazione: (2025)

Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population
di: Kevin Cowart, et al.
Pubblicazione: (2025)

Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis
di: Daniel G. K. Rasmussen, et al.
Pubblicazione: (2024)

Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the ONWARDS 1–5 trials
di: Harpreet S. Bajaj, et al.
Pubblicazione: (2024)

Comparative prognostic value of nine cardiorenal biomarkers for mortality among adults with prediabetes and diabetes
di: Chunyan Chai, et al.
Pubblicazione: (2026)

A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
di: Panpan Xie, et al.
Pubblicazione: (2024)

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States
di: Xi Tan, et al.
Pubblicazione: (2026)

Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo
di: Jianhua Ma, et al.
Pubblicazione: (2024)

Association of body roundness index with cardiovascular disease and all‐cause mortality among Chinese adults
di: Hong Lin, et al.
Pubblicazione: (2025)

Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c , BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5
di: Alice Y. Y. Cheng, et al.
Pubblicazione: (2025)

Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J‐mono post hoc analysis
di: Masato Yoneda, et al.
Pubblicazione: (2025)

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
di: Brandon K. Bergman, et al.
Pubblicazione: (2025)

Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
di: Weijun Gu, et al.
Pubblicazione: (2025)

Longitudinal exposure to non‐ HDL ‐C and cardiovascular events, all‐cause mortality in type 2 diabetes: A post hoc analysis of the ACCORD trial
di: Yueyue Wang, et al.
Pubblicazione: (2026)

Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
di: Chenyang Shi, et al.
Pubblicazione: (2024)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
di: Alpana P. Shukla, et al.
Pubblicazione: (2025)

Effects of reducing sedentary behaviour on renal glucose uptake during insulin stimulation: A post‐hoc analysis of a 6‐month randomized controlled trial
di: Eleni Rebelos, et al.
Pubblicazione: (2025)

Glucose‐dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes—A randomised placebo‐controlled study
di: Bjørn Hoe, et al.
Pubblicazione: (2025)

One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
di: Mengqing Zhang, et al.
Pubblicazione: (2024)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
di: Matthew J. Armstrong, et al.
Pubblicazione: (2024)

Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
di: Carel W. le Roux, et al.
Pubblicazione: (2024)

Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
di: Dario Giugliano, et al.
Pubblicazione: (2024)

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
di: Emily R. Hankosky, et al.
Pubblicazione: (2025)

Body mass index and remote ischaemic conditioning efficacy in acute ischaemic stroke patients: A post hoc analysis of the Remote Ischaemic Conditioning for Acute Moderate Ischaemic Stroke (RICAMIS) trial
di: Xiao‐Yu Sun, et al.
Pubblicazione: (2024)

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
di: Stergios A. Polyzos, et al.
Pubblicazione: (2026)

Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time‐in‐ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli‐D study
di: Juan Liu, et al.
Pubblicazione: (2025)

Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights
di: Pavol Kral, et al.
Pubblicazione: (2024)

Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”
di: Manish R. Bhise, et al.
Pubblicazione: (2025)

Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation
di: Weiping Jia, et al.
Pubblicazione: (2025)

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial
di: Luxcia Kugathasan, et al.
Pubblicazione: (2026)

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
di: Jason M. Samuels, et al.
Pubblicazione: (2025)

Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
di: Takefumi Kishimori, et al.
Pubblicazione: (2026)

Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
di: Noga C. Minsky, et al.
Pubblicazione: (2025)